Clinical Trials – Page 2 – media

A Scientifically-Supported App for Early Stage Dementia by SMART Brain Ageing

SMART Brain Aging, Inc. announced its one-on-one patient intervention program for aging brain health, Brain U Online, now available to adults above age 50 via online subscription and iOS app, Brain U Lite. Five years of clinical trials were carried out with more than 3,000 participants at Harvard Medical School/Boston University School of Medicine to develop this new program
- Source: HitConsultant
- 852
- July 10, 2018
Alzheimer's Clinical Trials Dementia mHealth
Biotech Crinetics Therapeutics Raises $86 million in IPO

The San Diego-based biotech company Crinetics Therapeutics recently raised $86 million in an IPO. Prior to the new funding, the company received $63.5 million in series B funding and will see its lead asset through phase 2.
- Source: FierceBiotech
- 806
- June 26, 2018
biotech Clinical Trials endocrine disorders
Nanobiotix NBTXR3 in Late Phase Clinical Trial

NBTXR3 is composed of crystalline nanoparticles to amplify the efficacy of radiation therapy. The idea is to administer NBTXR3 as intra-tumoral injections before external beam radiation therapy, thereby increasing the antitumor effect, and thus preparing the patient for surgical resection.
- Source: FierceBiotech
- 619
- June 26, 2018
cancer Clinical Trials radiation therapy
Re-Investigation on FDA Approved Anti-Gout Drug Uloric

When the FDA approved this drug, there was an additional demand from the FDA to conduct post-marketing studies and assess the drug’s safety. Recently, a non-profit consumer advocacy group sent a petition requesting that the FDA should eliminate the drug from the U.S. pharma market since the drug shows significant risk of cardiovascular diseases.
- Source: FiercePharma
- 693
- June 25, 2018
cardiovascular disease Clinical Trials gout Takeda
Smart Stent to Continuously Monitor Blood Flow

The smart stent looks similar to most commercial stents and uses medical-grade stainless steel. The researcher remarked that the devices as the first angioplasty smart stent, can be implanted in the patients without any modification in current medical procedures.
- Source: ScienceDaily
- 1,472
- June 22, 2018
Clinical Trials digital health medical device
Gout Treatment – Shift from Phase 2 to Phase 3 Trial

Previous interim data reported negative results due to which the stock value of Selecta Biosciences dropped down at once by 20% in premarket trading. It was then recovered in a remarkable manner by touching the never seen before peak level.
- Source: FierceBiotech
- 521
- June 21, 2018
Clinical Trials gout
Imutex Universal FLU Vaccine Reaching Phase 3

In phase 2b clinical trial work, FLU-v met its goal of boosting T-cell immune response at 42 days and 180 days after vaccination. The infection rate came down by meeting a secondary endpoint of boosting antibodies in vaccinated patients. Thus, this single adjuvant dose is considered as the "most immunological and efficient."
- Source: FiercePharma
- 901
- June 21, 2018
Clinical Trials flu influenza vaccine
What is COPD and how is it Treated?

Chronic obstructive pulmonary disease (COPD) is kind of lung disorder where the person may have difficulty in breathing which worsens over time. An irritation or inflammation in the lungs causes the air sacs to lose their elasticity, which leaves the air trapped in the lungs when you exhale. If this lasts too long, it could lead to a group of lung diseases (Chronic bronchitis and Emphysema) known as COPD.
- Source: HealthLine
- 695
- June 19, 2018
Clinical Trials COPD
Antidepressants or Talk Therapy? – Know with EEG

As individuals, people react in various ways to the same situation or event. This also rings true when it comes to effectively treating conditions such as depression or anxiety, which often makes it difficult to determine whether treatment is working.
- Source: ScienceDaily
- 574
- June 19, 2018
antidepressants Clinical Trials Depression
Calliditas Therapeutics Files to Raise $75 M for Kidney Disease Trial

Calliditas Therapeutics is planning to raise $75 million through an Initial Public Offering in Sweden. The new investment capital will help Calliditas fund a phase 3 clinical trial of autoimmune kidney disease anticipated to start later this year.
- Source: Fierce Biotech
- 738
- June 15, 2018
chronic kidney disease Clinical Trials funding

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.